Thomas Leggett is CFO at Black Diamond Therapeutics, Inc. (BDTX). They have made 6 open-market trades across 2 companies since 2020, most recently 2026-03-18.
CIK 0001774690
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| STOK | 13,476 | $326K |
| BDTX | 3,000 | $5K |
| Total | $331K |
Shares reported on the most recent Form 4, priced at the 2026-03-19 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| STOK | SELL | 2026-03-17 | 2026-03-19 | $32.14 | $293K | -4.5% | +6.9% | -11.4% |
| BDTX | SELL | 2021-01-08 | 2021-01-11 | $33.94 | $102K | -27.3% | -21.5% | -31.2% |
| BDTX | SELL | 2020-12-08 | 2020-12-10 | $33.88 | $167K | -2.3% | +0.5% | -23.6% |
| BDTX | SELL | 2020-11-09 | 2020-11-12 | $32.96 | $99K | -2.8% | -1.9% | -19.3% |
| BDTX | SELL | 2020-10-08 | 2020-10-09 | $33.53 | $101K | -12.9% | -5.4% | +0.3% |
| BDTX | SELL | 2020-09-14 | 2020-09-16 | $31.00 | $93K | -2.0% | +15.1% | +17.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.